Retinitis Pigmentosa Clinical Trial
— PupDynOfficial title:
New Methods of Dynamic Pupillometrics in Subjects With Visual and Color Vision Pathologies for the Detection, Functional Diagnosis and Follow-up of These Pathologies
NCT number | NCT04909398 |
Other study ID # | P17-05 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 22, 2018 |
Est. completion date | May 22, 2019 |
Verified date | May 2021 |
Source | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The development of new oculometry techniques allows fine and dynamic measurements of pupillary diameter and use in routine clinical practice. The preliminary results obtained with innovative devices on healthy sjuets make it possible to envisage a clinical study on a population of patients suffering from retinal pathologies. This is a "proof of concept" study, which, if the expected results are confirmed, will make it possible to consider a study on a larger population, as well as the industrial development of a commercial device.
Status | Completed |
Enrollment | 60 |
Est. completion date | May 22, 2019 |
Est. primary completion date | March 22, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Patients with an understanding of the French language to ensure a perfect understanding of the instructions during evaluations and documents relating to their involvement in the study. Visually impaired volunteers: Patients must have one of three conditions: Retinitis Pigmentosa, Stargardt disease, Leber optic neuropathy. Healthy volunteers: - Visual acuity of both corrected eyes (glasses) should be higher or equal 8/10th and a normal visual field. - Patients should not wear contact lenses (which may interfere with the recording of the pupil and eye movements) Exclusion Criteria: - Pregnant or lactating women will not be able to participate in this research. - Participants should not be unable to personally consent. - Subjects should not participate in another clinical trial that may interfere with this research. - Inability to personally consent. - Subjects should not present with degenerative diseases or any other disease that could interfere with the evaluations planned during this study. - The subject follows a drug treatment which can cause visual disturbances, changes in pupillary kinetics or cognitive disturbances. Secondary exclusion criteria (at the end of the inclusion visit): - Visually impaired subjects and controls for which calibration is not feasible. - Patients and control subjects having difficulty maintaining visual fixation. - Patients and subjects wearing corrective lenses making it impossible to record oculomotor activity with an infrared camera oculometer. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier National D'Ophtalùmologie des Quinze-Vingts | Paris |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | Streetlab |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dynamic pupillometry sessions pupillary reflex measurement | Measurement of the right eye / left eye and binocular monocular pupillary reflex: pupillary response measured for 5 seconds with 3 levels of screen luminance, each stimulation will be separated from the next by a delay of 5 seconds | Week 1 | |
Primary | RAPD measurement | Alternate stimulation of the right and left eye: 10 repetitions, each corresponding to the stimulation of one eye for one second. | Week 1 | |
Primary | Endogenous pupillary oscillation measurement | Pupil oscillation frequency, for each eye and in binocular: during this test the participants observe the stimulation screen (central fixation point) for 45 seconds during which the lumnance of the screen is calculated to be proportional to the size of the pupil
in real time. |
Week 1 | |
Primary | Measurement of pupillary activity by frequency marking | This test consists of the simultaneous presentation of 5 areas of the screen, each of which is luminance modulated at a specific frequency. | Week 1 | |
Primary | Pupillary measurement of color vision | In this test, 2 background colors alternate at low frequency over time.
The physical luminance of one color is fixed while the other is adaptively changed during a test to reduce pupillary response. |
Week 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |